{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T23:52:28Z","timestamp":1787701948282,"version":"build-2784847793"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T00:00:00Z","timestamp":1648512000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T00:00:00Z","timestamp":1648512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["AIRC-IG:11669"],"award-info":[{"award-number":["AIRC-IG:11669"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001755","name":"Mesothelioma Applied Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001755","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Diffuse malignant peritoneal mesothelioma (DMPM) is a rare and rapidly lethal tumor, poorly responsive to conventional treatments. In this regards, the identification of molecular alterations underlying DMPM onset and progression might be exploited to develop novel therapeutic strategies. Here, we focused on<jats:italic>miR-550a-3p<\/jats:italic>, which we found downregulated in 45 DMPM clinical samples compared to normal tissues and whose expression levels were associated with patient outcome. Through a gain-of-function approach using miRNA mimics in 3 DMPM cell lines, we demonstrated the tumor-suppressive role of<jats:italic>miR-550a-3p<\/jats:italic>. Specifically, miRNA ectopic expression impaired cell proliferation and invasiveness, enhanced the apoptotic response, and reduced the growth of DMPM xenografts in mice. Antiproliferative and proapoptotic effects were also observed in prostate and ovarian cancer cell lines following<jats:italic>miR-550a-3p<\/jats:italic>ectopic expression.<jats:italic>miR-550a-3p<\/jats:italic>effects were mediated, at least in part, by the direct inhibition of<jats:italic>HSP90AA1<\/jats:italic>and the consequent downregulation of its target proteins, the levels of which were rescued upon disruption of miRNA-<jats:italic>HSP90AA1<\/jats:italic>mRNA pairing, partially abrogating<jats:italic>miR-550a-3p<\/jats:italic>-induced cellular effects. Our results show that<jats:italic>miR-550a-3p<\/jats:italic>reconstitution affects several tumor traits, thus suggesting this approach as a potential novel therapeutic strategy for DMPM.<\/jats:p>","DOI":"10.1038\/s41417-022-00460-7","type":"journal-article","created":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T20:31:55Z","timestamp":1648585915000},"page":"1394-1404","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["miR-550a-3p is a prognostic biomarker and exerts tumor-suppressive functions by targeting HSP90AA1 in diffuse malignant peritoneal mesothelioma"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2384-169X","authenticated-orcid":false,"given":"Rihan","family":"El Bezawy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Percio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara Maura","family":"Ciniselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelandrea","family":"De Cesare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennaro","family":"Colella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Dugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Veneroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4800-0961","authenticated-orcid":false,"given":"Valentina","family":"Doldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9314-5230","authenticated-orcid":false,"given":"Silvia","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Baratti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Kusamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Verderio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Deraco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7811-3377","authenticated-orcid":false,"given":"Paolo","family":"Gandellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4669-0890","authenticated-orcid":false,"given":"Nadia","family":"Zaffaroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7882-9095","authenticated-orcid":false,"given":"Valentina","family":"Zuco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,29]]},"reference":[{"key":"460_CR1","doi-asserted-by":"publisher","first-page":"915","DOI":"10.21037\/jgo.2017.08.01","volume":"8","author":"A Garc\u00eda-Fadrique","year":"2017","unstructured":"Garc\u00eda-Fadrique A, Mehta A, Mohamed F, Dayal S, Cecil T, Moran BJ. Clinical presentation, diagnosis, classification and management of peritoneal mesothelioma: a review. J Gastrointest Oncol. 2017;8:915\u201324. https:\/\/doi.org\/10.21037\/jgo.2017.08.01","journal-title":"J Gastrointest Oncol"},{"key":"460_CR2","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1245\/s10434-018-6337-5","volume":"25","author":"HR Alexander Jr","year":"2018","unstructured":"Alexander HR Jr, Li CY, Kennedy TJ. Current management and future opportunities for peritoneal metastases: peritoneal mesothelioma. Ann Surg Oncol. 2018;25:2159\u201364. https:\/\/doi.org\/10.1245\/s10434-018-6337-5","journal-title":"Ann Surg Oncol"},{"key":"460_CR3","doi-asserted-by":"publisher","first-page":"433","DOI":"10.4149\/neo_2014_053","volume":"61","author":"H Kaya","year":"2014","unstructured":"Kaya H, Sezg\u0131 C, Tanr\u0131kulu AC, Taylan M, Abakay O, Sen HS, et al. Prognostic factors influencing survival in 35 patients with malignant peritoneal mesothelioma. Neoplasma. 2014;61:433\u20138. https:\/\/doi.org\/10.4149\/neo_2014_053","journal-title":"Neoplasma."},{"key":"460_CR4","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.surg.2013.01.001","volume":"153","author":"HR Alexander Jr","year":"2013","unstructured":"Alexander HR Jr, Bartlett DL, Pingpank JF, Libutti SK, Royal R, Hughes MS, et al. Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery. 2013;153:779\u201386. https:\/\/doi.org\/10.1016\/j.surg.2013.01.001","journal-title":"Surgery."},{"key":"460_CR5","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1245\/s10434-014-3978-x.","volume":"22","author":"JH Helm","year":"2015","unstructured":"Helm JH, Miura JT, Glenn JA, Marcus RK, Larrieux G, Jayakrishnan TT, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Ann Surg Oncol. 2015;22:1686\u201393. https:\/\/doi.org\/10.1245\/s10434-014-3978-x.","journal-title":"Ann Surg Oncol"},{"key":"460_CR6","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1016\/j.ejca.2013.05.027","volume":"49","author":"D Baratti","year":"2013","unstructured":"Baratti D, Kusamura S, Cabras AD, Bertulli R, Hutanu I, Deraco M. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Cancer. 2013;49:3140\u20138. https:\/\/doi.org\/10.1016\/j.ejca.2013.05.027","journal-title":"Eur J Cancer"},{"key":"460_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-019-0620-3.","volume":"11","author":"R Shrestha","year":"2019","unstructured":"Shrestha R, Nabavi N, Lin YY, Mo F, Anderson S, Volik S, et al. BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma. Genome Med. 2019;11:8 https:\/\/doi.org\/10.1186\/s13073-019-0620-3.","journal-title":"Genome Med"},{"key":"460_CR8","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/modpathol.2016.188.","volume":"30","author":"NM Joseph","year":"2017","unstructured":"Joseph NM, Chen YY, Nasr A, Yeh I, Talevich E, Onodera C, et al. Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X. Mod Pathol. 2017;30:246\u201354. https:\/\/doi.org\/10.1038\/modpathol.2016.188.","journal-title":"Mod Pathol"},{"key":"460_CR9","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1001\/jamaoncol.2017.2918.","volume":"4","author":"YP Hung","year":"2018","unstructured":"Hung YP, Dong F, Watkins JC, Nardi V, Bueno R, Dal Cin P, et al. Identification of ALK rearrangements in malignant peritoneal mesothelioma. JAMA Oncol. 2018;4:235\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2017.2918.","journal-title":"JAMA Oncol"},{"key":"460_CR10","doi-asserted-by":"publisher","first-page":"D155","DOI":"10.1093\/nar\/gky1141.","volume":"47","author":"A Kozomara","year":"2019","unstructured":"Kozomara A, Birgaoanu M, Griffiths-Jones S. miRBase: from microRNA sequences to function. Nucleic Acids Res. 2019;47:D155\u2013D162. https:\/\/doi.org\/10.1093\/nar\/gky1141.","journal-title":"Nucleic Acids Res"},{"key":"460_CR11","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1146\/annurev-biochem-060308-103103","volume":"79","author":"MR Fabian","year":"2010","unstructured":"Fabian MR, Sonenberg N, Filipowicz W. Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem. 2010;79:351\u201379. https:\/\/doi.org\/10.1146\/annurev-biochem-060308-103103. Review. PubMed PMID: 20533884","journal-title":"Annu Rev Biochem"},{"key":"460_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ydbio.2006.08.028","volume":"302","author":"B Zhang","year":"2007","unstructured":"Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol. 2007;302:1\u201312. https:\/\/doi.org\/10.1016\/j.ydbio.2006.08.028","journal-title":"Dev Biol"},{"key":"460_CR13","doi-asserted-by":"publisher","unstructured":"Fortunato O, Iorio MV. The therapeutic potential of microRNAs in cancer: illusion or opportunity?. Pharmaceuticals (Basel). 2020. https:\/\/doi.org\/10.3390\/ph13120438.","DOI":"10.3390\/ph13120438"},{"key":"460_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13045-016-0387-6","volume":"10","author":"R El Bezawy","year":"2017","unstructured":"El Bezawy R, De Cesare M, Pennati M, Deraco M, Gandellini P, Zuco V, et al. Antitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanism. J Hematol Oncol. 2017;10:19 https:\/\/doi.org\/10.1186\/s13045-016-0387-6","journal-title":"J Hematol Oncol"},{"key":"460_CR15","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13045-017-0510-3","volume":"10","author":"G Cimino-Reale","year":"2017","unstructured":"Cimino-Reale G, Gandellini P, Santambrogio F, Recagni M, Zaffaroni N, Folini M. miR-380-5p-mediated repression of TEP1 and TSPYL5 interferes with telomerase activity and favours the emergence of an \u201cALT-like\u201d phenotype in diffuse malignant peritoneal mesothelioma cells. J Hematol Oncol. 2017;10:140 https:\/\/doi.org\/10.1186\/s13045-017-0510-3","journal-title":"J Hematol Oncol"},{"key":"460_CR16","doi-asserted-by":"publisher","first-page":"13119","DOI":"10.18632\/oncotarget.3761","volume":"6","author":"M De Cesare","year":"2015","unstructured":"De Cesare M, Cominetti D, Doldi V, Lopergolo A, Deraco M, Gandellini P, et al. Anti-tumor activity of selective inhibitors of XPO1\/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin. Oncotarget. 2015;6:13119\u201332. https:\/\/doi.org\/10.18632\/oncotarget.3761","journal-title":"Oncotarget."},{"key":"460_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-016-0781-4","volume":"14","author":"M De Cesare","year":"2016","unstructured":"De Cesare M, Sfondrini L, Pennati M, De Marco C, Motta V, Tagliabue E, et al. CpG-oligodeoxynucleotides exert remarkable antitumor activity against diffuse malignant peritoneal mesothelioma orthotopic xenografts. J Transl Med. 2016;14:25 https:\/\/doi.org\/10.1186\/s12967-016-0781-4.","journal-title":"J Transl Med."},{"key":"460_CR18","doi-asserted-by":"publisher","first-page":"7223","DOI":"10.1021\/acs.jmedchem.6b00777","volume":"59","author":"V Span\u00f2","year":"2016","unstructured":"Span\u00f2 V, Pennati M, Parrino B, Carbone A, Montalbano A, Cilibrasi V, et al. Preclinical activity of new [1,2]oxazolo[5,4-e]isoindole derivatives in diffuse malignant peritoneal mesothelioma. J Med Chem. 2016;59:7223\u201338. https:\/\/doi.org\/10.1021\/acs.jmedchem.6b00777","journal-title":"J Med Chem"},{"key":"460_CR19","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1023\/a:1008265012435","volume":"9","author":"P Perego","year":"1998","unstructured":"Perego P, Romanelli S, Carenini N, Magnani I, Leone R, Bonetti A, et al. Ovarian cancer cisplatin-resistant cell lines: multiple changes including collateral sensitivity to Taxol. Ann Oncol. 1998;9:423\u201330. https:\/\/doi.org\/10.1023\/a:1008265012435","journal-title":"Ann Oncol"},{"key":"460_CR20","first-page":"556","volume":"56","author":"P Perego","year":"1996","unstructured":"Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, et al. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res. 1996;56:556\u201362.","journal-title":"Cancer Res"},{"key":"460_CR21","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1093\/jnci\/djh184","volume":"96","author":"G Cuccuru","year":"2004","unstructured":"Cuccuru G, Lanzi C, Cassinelli G, Pratesi G, Tortoreto M, Petrangolini G, et al. Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma. J Natl Cancer Inst. 2004;96:1006\u201314. https:\/\/doi.org\/10.1093\/jnci\/djh184","journal-title":"J Natl Cancer Inst"},{"key":"460_CR22","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.bcp.2009.09.012","volume":"79","author":"V Zuco","year":"2010","unstructured":"Zuco V, Supino R, Favini E, Tortoreto M, Cincinelli R, Croce AC, et al. Efficacy of ST1968 (namitecan) on a topotecan-resistant squamous cell carcinoma. Biochem Pharmacol. 2010;79:535\u201341. https:\/\/doi.org\/10.1016\/j.bcp.2009.09.012","journal-title":"Biochem Pharmacol"},{"key":"460_CR23","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1093\/bioinformatics\/btn224","volume":"24","author":"P Du","year":"2008","unstructured":"Du P, Kibbe WA, Lin SM. lumi: a pipeline for processing Illumina microarray. Bioinformatics. 2008;24:1547\u20138. https:\/\/doi.org\/10.1093\/bioinformatics\/btn224","journal-title":"Bioinformatics."},{"key":"460_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2004-5-10-r80","volume":"5","author":"RC Gentleman","year":"2004","unstructured":"Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5:R80 https:\/\/doi.org\/10.1186\/gb-2004-5-10-r80","journal-title":"Genome Biol"},{"key":"460_CR25","doi-asserted-by":"publisher","first-page":"Article3","DOI":"10.2202\/1544-6115.1027","volume":"3","author":"GK Smyth","year":"2004","unstructured":"Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004;3:Article3 https:\/\/doi.org\/10.2202\/1544-6115.1027","journal-title":"Stat Appl Genet Mol Biol"},{"key":"460_CR26","unstructured":"Hollander M, Wolfe DA. Nonparametric Statistical Methods. 2nd edition, NewYork: John Wiley & Sons, 1999."},{"key":"460_CR27","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox DR. Regression models and life tables (with discussion). JR Stat Soc B. 1972;34:187\u2013220.","journal-title":"JR Stat Soc B"},{"key":"460_CR28","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statis Assn. 1958;53:457\u201381.","journal-title":"J Am Statis Assn"},{"key":"460_CR29","doi-asserted-by":"publisher","unstructured":"Agarwal V, Bell GW, Nam JW, Bartel DP. Predicting effective microRNA target sites in mammalian mRNAs. elife. 2015. https:\/\/doi.org\/10.7554\/eLife.05005.","DOI":"10.7554\/eLife.05005"},{"key":"460_CR30","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.gene.2015.06.018","volume":"570","author":"AD Zuehlke","year":"2015","unstructured":"Zuehlke AD, Beebe K, Neckers L, Prince T. Regulation and function of the human HSP90AA1 gene. Gene. 2015;570:8\u201316. https:\/\/doi.org\/10.1016\/j.gene.2015.06.018","journal-title":"Gene."},{"key":"460_CR31","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1038\/sj.onc.1210893","volume":"27","author":"K Lin","year":"2008","unstructured":"Lin K, Rockliffe N, Johnson GG, Sherrington PD, Pettitt AR. Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53\/ATM status in chronic lymphocytic leukaemia cells. Oncogene. 2008;27:2445\u201355. https:\/\/doi.org\/10.1038\/sj.onc.1210893","journal-title":"Oncogene."},{"key":"460_CR32","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1158\/1541-7786.MCR-10-0534","volume":"9","author":"D Li","year":"2011","unstructured":"Li D, Marchenko ND, Schulz R, Fischer V, Velasco-Hernandez T, Talos F, et al. Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells. Mol Cancer Res. 2011;9:577\u201388. https:\/\/doi.org\/10.1158\/1541-7786.MCR-10-0534","journal-title":"Mol Cancer Res"},{"key":"460_CR33","doi-asserted-by":"publisher","first-page":"118123","DOI":"10.1016\/j.lfs.2020.118123","volume":"257","author":"M Gandhi","year":"2020","unstructured":"Gandhi M, Nair S. New vistas in malignant mesothelioma: microRNA architecture and NRF2\/MAPK signal transduction. Life Sci. 2020;257:118123 https:\/\/doi.org\/10.1016\/j.lfs.2020.118123","journal-title":"Life Sci"},{"key":"460_CR34","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.canlet.2015.02.026","volume":"360","author":"GD Lianos","year":"2015","unstructured":"Lianos GD, Alexiou GA, Mangano A, Mangano A, Rausei S, Boni L, et al. The role of heat shock proteins in cancer. Cancer Lett. 2015;360:114\u20138. https:\/\/doi.org\/10.1016\/j.canlet.2015.02.026","journal-title":"Cancer Lett"},{"key":"460_CR35","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.tibs.2006.01.006","volume":"31","author":"SK Calderwood","year":"2006","unstructured":"Calderwood SK, Khaleque MA, Sawyer DB, Ciocca DR. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci. 2006;31:164\u201372. https:\/\/doi.org\/10.1016\/j.tibs.2006.01.006","journal-title":"Trends Biochem Sci"},{"key":"460_CR36","doi-asserted-by":"publisher","first-page":"639596","DOI":"10.3389\/fcell.2021.639596","volume":"9","author":"H Liu","year":"2021","unstructured":"Liu H, Zhang Z, Huang Y, Wei W, Ning S, Li J, et al. Plasma HSP90AA1 predicts the risk of breast cancer onset and distant metastasis. Front Cell Dev Biol. 2021;9:639596 https:\/\/doi.org\/10.3389\/fcell.2021.639596","journal-title":"Front Cell Dev Biol"},{"key":"460_CR37","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/CEJ.0000000000000549","volume":"29","author":"W Chen","year":"2020","unstructured":"Chen W, Li G, Peng J, Dai W, Su Q, He Y. Transcriptomic analysis reveals that heat shock protein 90\u03b1 is a potential diagnostic and prognostic biomarker for cancer. Eur J Cancer Prev. 2020;29:357\u201364. https:\/\/doi.org\/10.1097\/CEJ.0000000000000549","journal-title":"Eur J Cancer Prev"},{"key":"460_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-020-01296-7","volume":"20","author":"G Fan","year":"2020","unstructured":"Fan G, Tu Y, Wu N, Xiao H. The expression profiles and prognostic values of HSPs family members in Head and neck cancer. Cancer Cell Int. 2020;20:220 https:\/\/doi.org\/10.1186\/s12935-020-01296-7","journal-title":"Cancer Cell Int"},{"key":"460_CR39","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1093\/carcin\/bgi289","volume":"103","author":"DT Jones","year":"2004","unstructured":"Jones DT, Addison E, North JM, Lowdell MW, Hoffbrand AV, et al. Geldanamycin and herbimycin A induce apoptotic killing of B chronic lymphocytic leukemia cells and augment the cells\u2019 sensitivity to cytotoxic drugs. Blood. 2004a;103:1855\u201361. https:\/\/doi.org\/10.1093\/carcin\/bgi289","journal-title":"Blood."},{"key":"460_CR40","doi-asserted-by":"publisher","first-page":"11942","DOI":"10.1158\/0008-5472.CAN-07-3162","volume":"67","author":"J Phillip","year":"2007","unstructured":"Phillip J, Gray MaryAnnStevenson Jr, Stuart KCalderwood. Targeting Cdc37 inhibits multiple signaling pathways and induces growth arrest in prostate cancer cells. Cancer Res. 2007;67:11942\u201350. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-3162","journal-title":"Cancer Res"},{"key":"460_CR41","doi-asserted-by":"publisher","unstructured":"Wang L, Zhang L, Li L, Jiang J, Zheng Z, Shang J, et al. Small-molecule inhibitor targeting the Hsp90-Cdc37 protein-protein interaction in colorectal cancer. Sci Adv. 2019. https:\/\/doi.org\/10.1126\/sciadv.aax2277","DOI":"10.1126\/sciadv.aax2277"},{"key":"460_CR42","doi-asserted-by":"publisher","first-page":"53853","DOI":"10.18632\/oncotarget.10793","volume":"7","author":"JY Ho","year":"2016","unstructured":"Ho JY, Hsu RJ, Wu CH, Liao GS, Gao HW, Wang TH, et al. Reduced miR-550a-3p leads to breast cancer initiation, growth, and metastasis by increasing levels of ERK1 and 2. Oncotarget. 2016;7:53853\u201368. https:\/\/doi.org\/10.18632\/oncotarget.10793","journal-title":"Oncotarget."},{"key":"460_CR43","doi-asserted-by":"publisher","first-page":"4156","DOI":"10.26355\/eurrev_201807_15408","volume":"22","author":"JZ Yang","year":"2018","unstructured":"Yang JZ, Bian L, Hou JG, Wang HY. MiR-550a-3p promotes non-small cell lung cancer cell proliferation and metastasis through down-regulating TIMP2. Eur Rev Med Pharmacol Sci. 2018;22:4156\u201365. https:\/\/doi.org\/10.26355\/eurrev_201807_15408","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"460_CR44","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1515\/med-2020-0111","volume":"15","author":"J Xiong","year":"2020","unstructured":"Xiong J, Xue Y, Xia Y, Zhao J, Wang Y. Identification of key microRNAs of plasma extracellular vesicles and their diagnostic and prognostic significance in melanoma. Open Med (Wars). 2020;15:464\u201382. https:\/\/doi.org\/10.1515\/med-2020-0111","journal-title":"Open Med (Wars)"},{"key":"460_CR45","doi-asserted-by":"publisher","first-page":"23581","DOI":"10.1002\/jcp.28927","volume":"234","author":"L Qin","year":"2019","unstructured":"Qin L, Huang J, Wang G, Huang J, Wu X, Li J, et al. Integrated analysis of clinical significance and functional involvement of microRNAs in hepatocellular carcinoma. J Cell Physiol. 2019;234:23581\u201395. https:\/\/doi.org\/10.1002\/jcp.28927","journal-title":"J Cell Physiol"},{"key":"460_CR46","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1038\/s41416-020-0802-1","volume":"122","author":"DS Hong","year":"2020","unstructured":"Hong DS, Kang YK, Borad M, Sachdev J, Ejadi S, Lim HY, et al. Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. Br J Cancer. 2020;122:1630\u20137. https:\/\/doi.org\/10.1038\/s41416-020-0802-1","journal-title":"Br J Cancer."},{"key":"460_CR47","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.21037\/tlcr.2017.12.01","volume":"7","author":"S Viteri","year":"2018","unstructured":"Viteri S, Rosell R. An innovative mesothelioma treatment based on miR-16 mimic loaded EGFR targeted minicells (TargomiRs). Transl Lung Cancer Res. 2018;7:S1\u2013S4. https:\/\/doi.org\/10.21037\/tlcr.2017.12.01","journal-title":"Transl Lung Cancer Res."},{"key":"460_CR48","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/S1470-2045(17)30621-6","volume":"18","author":"N van Zandwijk","year":"2017","unstructured":"van Zandwijk N, Pavlakis N, Kao SC, Linton A, Boyer MJ, Clarke S, et al. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. Lancet Oncol. 2017;18:1386\u201396. https:\/\/doi.org\/10.1016\/S1470-2045(17)30621-6","journal-title":"Lancet Oncol"},{"key":"460_CR49","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/carcin\/bgz183","volume":"41","author":"L Witten","year":"2020","unstructured":"Witten L, Slack FJ. miR-155 as a novel clinical target for hematological malignancies. Carcinogenesis. 2020;41:2\u20137. https:\/\/doi.org\/10.1093\/carcin\/bgz183","journal-title":"Carcinogenesis."},{"key":"460_CR50","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/cancers13112680","volume":"29","author":"S Reda El Sayed","year":"2021","unstructured":"Reda El Sayed S, Cristante J, Guyon L, Denis J, Chabre O, et al. MicroRNA therapeutics in cancer: current advances and challenges. Cancers (Basel). 2021;29:13 https:\/\/doi.org\/10.3390\/cancers13112680","journal-title":"Cancers (Basel)"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41417-022-00460-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-022-00460-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-022-00460-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T06:27:00Z","timestamp":1726900020000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-022-00460-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,29]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["460"],"URL":"https:\/\/doi.org\/10.1038\/s41417-022-00460-7","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,29]]},"assertion":[{"value":"3 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The use of the patient samples and information was approved by the Institutional Review Board of INT. Written informed consent was obtained from all patients to donate the leftover tissue to INT after diagnostic and clinical procedures. Animal experiments were approved by the Ethics Committee for Animal Experimentation of INT, authorized by the Italian Ministry of Health according to the national law (Project approval code: 1120\/2015-PR), and performed in compliance with international policies and guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}